Turnstone receives IND clearance for phase I trial of TIDAL-01 for solid tumors
Nov. 2, 2022
Turnstone Biologics Corp. has received IND clearance from the FDA for the company's lead selected tumor-infiltrating lymphocyte (TIL) therapy program, TIDAL-01.